Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

12.01.2015: WILEX subsidiary Heidelberg Pharma receives research grant for development of PSMA antibody drug conjugates.WILEX AG today announced that its subsidiary Heidelberg Pharma has been awarded a research grant for the further development of PSMA-antibody drug conjugates (ADCs) to treat prostate cancer....More


Seite gelesen: 222748 | Heute: 82